INCENTIVIZING DRUG AFFORDABILITY: WILDCARD EXCLUSIVITY VOUCHERS.

The article explores the issue of drug affordability and the impact of patents and monopolies on access to medication. It discusses the differences between innovator and generic pharmaceutical companies and the problem of delayed generic access. The article proposes the use of incentive programs, such as wildcard exclusivity vouchers, to encourage innovator companies to lower prices and increase generic competition. It also discusses the advantages and potential benefits of these incentive programs for patients and the healthcare system. The article further examines strategies used by pharmaceutical companies to delay generic competition and maintain monopolies, such as reverse payment settlements and evergreening. It concludes by discussing the potential effectiveness of FDA priority review vouchers and wildcard exclusivity vouchers in improving drug affordability and access. [Extracted from the article]